- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01633541
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have pathologically confirmed, previously untreated, resectable, squamous cell carcinoma of the larynx or hypopharynx.
- Disease must be Stage III or IV
- Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy
- Patients must undergo pre-treatment endoscopic tumor staging and CT scanning
- ECOG Performance status 0-1
- Adequate WBC (white blood cell), granulocyte and platelet counts
- Creatinine clearance of ≥ 60cc/min for cisplatin candidates and ≥ 30 cc/min for carboplatin candidates
- Adequate bilirubin, AST (aspartate aminotransferase), and ALT (alanine transaminase) function
Exclusion Criteria:
- Prior head and neck malignancy or history of other prior non-head and neck malignancy within the past 3 years
- Prior head and neck radiation or prior chemotherapy.
- Documented evidence of distant metastases
- Active infection
- Pregnancy or lactation
- Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment
- Patients residing in prison
- Patients with psychiatric/ social situations that would limit compliance with study requirements
- Patients with Grade > 2 peripheral neuropathy
- History of severe hypersensitivity reaction to docetaxel
- Class 3 or 4 cardiac disease
- Unstable angina or history of myocardial ischemia within prior 6 months
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, partial or complete small bowel obstruction
- Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101
- Patients taking any other concurrent approved or investigational anti-cancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Comparator arm
(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6). Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies. |
Cisplatin 100 mg/m2
Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
Docetaxel (Taxotere) 75 mg/m2
Other Names:
|
Experimental: platinum/docetaxel + AT-101
platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist. (Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6). (AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy. |
Patients will receive AT-101 40 mg orally two times a day.
Other Names:
Cisplatin 100 mg/m2
Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment
Time Frame: Up to 3 months after end of treatment
|
The primary clinical objective of this trial is to compare the larynx preservation rates in a treatment paradigm that uses induction chemotherapy plus AT-101 to select patients for either concurrent chemoradiation or surgery.
Organ preservation rate, defined as alive and free from indication for laryngectomy three months post treatment, was chosen as the primary endpoint because it provides evidence to fully characterize clinically the effect of the treatment strategy
|
Up to 3 months after end of treatment
|
Progression-free Survival
Time Frame: Up to 3 years after randomization
|
Time from randomization to the time of first indication of local failure or metastases.
Estimated non-parametrically using the Kaplan-Meier method.
|
Up to 3 years after randomization
|
Overall Response Rate (ORR)
Time Frame: Up to approximately 60 days
|
ORR (Complete Response [CR] plus Partial Response [PR]) to induction chemotherapy with platinum and docetaxel plus AT-101 following one and/or two cycles in patients with advanced laryngeal cancer.
|
Up to approximately 60 days
|
Percentage of Patients Experiencing Grade 3 or Higher Adverse Events.
Time Frame: Up to 3 years after end of treatment
|
Toxicities will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 3.
|
Up to 3 years after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Head and Neck Related Quality of Life (QOL)
Time Frame: Up to 28 months post treatment
|
University of Michigan Head and Neck Quality of Life Instrument (HN-QOL) will be administered prior to treatment (i.e.
pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated).
Scale is 0-100 with high scores indicating a better outcome.
|
Up to 28 months post treatment
|
Voice Related QOL
Time Frame: Up to 28 months post treatment
|
The University of Michigan Voice Related Quality of Life Measure (V-RQOL) will be administered prior to treatment (i.e.
pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated).
Scale is 0-50 (10 items scale 1-5) with high scores indicating a worse outcome.
|
Up to 28 months post treatment
|
Functional Assessment QOL
Time Frame: Up to 28 months post treatment
|
University of Michigan Head and Neck Quality of Life Instrument (HN-QOL) will be administered prior to treatment (i.e.
pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated).
Scale is 0-100 with high scores indicating a better outcome.
EATING Domain is reported here as a functional assessment.
|
Up to 28 months post treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paul Swiecicki, MD, University of Michigan Rogel Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Otorhinolaryngologic Diseases
- Laryngeal Diseases
- Laryngeal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Carboplatin
Other Study ID Numbers
- UMCC 2010.101
- HUM00043975 (Other Identifier: University of Michigan IRBMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laryngeal Cancer
-
University Hospital OstravaRecruitingLaryngeal Disease | Laryngeal Lesions | Hypopharyngeal Lesions | Suspected Laryngeal Cancer | Suspected Hypopharyngeal Cancer | Proven Laryngeal Cancer | Proven Hypopharyngeal CancerCzechia
-
Thomas Jefferson UniversityCompletedHead and Neck Carcinoma | Lung Carcinoma | Oral Cavity Carcinoma | Paranasal Sinus Carcinoma | Stage III Laryngeal Cancer AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Stage IVA Laryngeal Cancer AJCC v8 | Stage IVB Laryngeal Cancer AJCC v8 | Stage IVC Laryngeal... and other conditionsUnited States
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
Centre Hospitalier Universitaire de NīmesCompleted
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingHead and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage IIINetherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8United States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownRecurrent Laryngeal CancerChina
-
Daping Hospital and the Research Institute of Surgery...Recruiting
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedRecurrent Laryngeal CancerChina
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedOral Complications of Radiation Therapy | Stage I Laryngeal Cancer | Stage II Laryngeal CancerUnited States
Clinical Trials on AT-101
-
TR TherapeuticsCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteMinneamrita Therapeutics LLCTerminatedAcute Myeloid LeukemiaUnited States
-
Ascenta TherapeuticsCompletedFollicular LymphomaUnited States
-
Brigham and Women's HospitalRecruiting
-
Alaunos TherapeuticsCompleted
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States
-
University of Michigan Rogel Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Alaunos TherapeuticsCompleted